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Abstract
Background: Diagnosis of cytomegalovirus (CMV) infection is challenging because of the high rate of
asymptomatic infection and the low specificity of associated symptoms and signs. As a result, laboratory testing is
an essential aid in making an accurate diagnosis. The presence of CMV IgM is indicative of primary CMV infection.
In pregnancy, diagnosis of primary infection is important because primary maternal infection increases fetal
infection risk substantially. Fetal infection can result in serious sequelae ranging from neurological deficits to death.
Diagnosis among the immunocompromised is also critical for the timely initiation of therapy that can reduce
morbidity and mortality risk.
Methods: The IMMULITE
® 2000 CMV IgM assay qualitatively detects CMV IgM antibodies in human serum or
plasma to aid in the diagnosis of current or recent CMV infection. To determine expected values in apparently
healthy subjects, 136 samples were tested. Reproducibility, normal range, and method comparison studies were
also performed to evaluate the assay’s performance. The assay’s reproducibility was evaluated across three sites.
Seven hundred and eighteen (n = 718) individual patient serum samples, which included samples from CMV IgM-
positive (n = 109, determined by the Abbott IMx CMV or the Diamedix CMV IgM assays), pregnant (n = 210), HIV-
positive (n = 30), immunosuppressed (n = 102), and transplant patients (n = 17) and from patients with potentially
cross-reacting conditions (n = 136) were evaluated in the method comparison study. The positive, negative, and
overall agreement between the IMMULITE 2000 CMV IgM assay and the VIDAS CMV IgM assay (predicate assay)
were determined.
Results: The assay demonstrated excellent reproducibility with a total CV of less than 10%. The positive, negative,
and overall agreement between the IMMULITE 2000 assay and the VIDAS assay were > 95% for the method
comparison samples. Among potentially cross-reactive samples, the overall agreement between the two assays was
96%. Similarly, among the immunocompromised and pregnant subjects, the overall agreement was ~96% and
~97%, respectively.
Conclusions: The IMMULITE 2000 CMV IgM assay demonstrated excellent reproducibility, minimal cross-reactivity,
and performance comparable to that of the VIDAS CMV IgM assay. It can aid in the diagnosis of acute CMV or
recent CMV infection by qualitatively detecting the CMV IgM antibodies in human serum or plasma.
Background
Cytomegalovirus (CMV) infection affects all age groups,
and there is no vaccine available. It is spread through
direct exposure to infected body fluids such as urine,
blood, breast milk, and saliva or via transplant of
infected organs [1,2]. CMV infections in healthy indivi-
duals are generally asymptomatic, and when symptoms
occur they are typically mild, nonspecific and self-limit-
ing. As a result, diagnosis of CMV infection is challen-
ging, and laboratory testing is an essential aid in making
an accurate diagnosis.
In pregnancy and among the immunocompromised,
CMV infection can have severe consequences, and thus,
in these groups, laboratory testing is a vital aid in facili-
tating timely, appropriate interventions. Cytomegalovirus
is the leading cause of congenital viral infection world-
wide, with an incidence of 0.5% to 3% of live births
[3,4]. It is also a leading cause of deafness and mental
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any medium, provided the original work is properly cited.retardation. Transmission rates from mother to fetus are
dependent on the type of maternal infection. In preg-
nancies with primary infection, the rate of fetal infection
is approximately 32% to 38% [1]. In comparison, in
pregnancies with reactivation or reinfection, the rate of
fetal infection is only ~1% [1-3].
Infection in early pregnancy is associated with more
severe sequelae, and congenital CMV disease is most
likely after a primary maternal infection [1,3,4].
Among the immunocompromised, CMV infection
(primary, reinfection, or reactivation) is associated with
increased morbidity and mortality. Symptomatic CMV
infection occurs in 20% to 60% of transplant recipients
[5].
Diagnosis of CMV infection and the type of infection
is based on a combination of tests, including tests that
measure or detect IgM, IgG, or IgG avidity. CMV IgM
plays an important role in the diagnosis of CMV infec-
tion. The presence of IgM is indicative of acute or pri-
mary infection, and the presence of IgG is indicative of
past infection. When both IgM and IgG are positive, the
level of IgG avidity is used to distinguish acute/primary
infection from past infection [4]. This study assessed the
performance of the fully automated IMMULITE 2000
CMV IgM assay.
Methods
The IMMULITE 2000 CMV IgM assay is for the quali-
tative detection of IgM antibodies to CMV in human
serum or plasma, as an aid in the diagnosis of current
or recent CMV infection (Table 1). It is an automated
solid phase enzyme-linked chemiluminescent three-step
immunoassay. The VIDAS
® CMV IgM assay is intended
to be used as an aid in the diagnosis of cytomegalovirus
infection (Table 1). It is an automated enzyme-linked
fluorescent immunoassay for the qualitative detection of
CMV IgM antibodies in human serum. Both the
IMMULITE and VIDAS CMV IgM assays were per-
formed according to the manufacturer’s instructions.
To evaluate the IMMULITE 2000 CMV IgM assay’s
performance, reproducibility, normal range, and method
comparison studies were performed.
The reproducibility study was conducted at three sites
using serum pools. Three serum pools were used: high
negative (70%-80% of the cutoff), around the cutoff
(110%-120% of the cutoff), and medium/high positive
(200%-250% of the cutoff). Two runs per day were con-
ducted over 5 days at each site. Each run included four
replicates of each serum pool for a total of 40 replicates
per sample at each site. Negative and positive kit con-
trols were included in each run for quality control.
To determine expected values in apparently healthy
subjects, 136 serum specimens were collected from
healthy asymptomatic subjects with no known evidence
of exposure to CMV. Samples were collected with
informed consent and Institutional Review Board
approval.
The method comparison study compared the IMMU-
LITE 2000 CMV IgM assay to the VIDAS CMV IgM
assay. A total of 718 individual patient serum samples
were tested. These included samples from from CMV
IgM-positive (109 determined by the Abbott IMx CMV
IgM or the Diamedix CMV IgM assays), pregnant (210),
HIV-positive (30), immunosuppressed (102), and trans-
plant patients (17), and from patients with potentially
cross-reactive conditions (136). Potentially cross-reacting
conditions were determined based on the results of
FDA-cleared immunoassays and included 60 antinuclear
antibody (ANA), 23 Epstein-Barr virus (EBV), 3 herpes
simplex, 25 rheumatoid factor (RF), and 25 rubella posi-
tive samples. In the analysis of sample subgroups, some
samples qualified for multiple subgroup classifications.
Positive, negative and overall agreement and 95% confi-
dence intervals were determined. Equivocal (VIDAS)
and indeterminate (IMMULITE) results were excluded
from the agreement analysis.
Results
The IMMULITE 2000 CMV IgM assay demonstrated
excellent reproducibility, minimal cross-reactivity, and
performance comparable to that of the predicate assay.
The 95th percentile values in apparently healthy subjects
supported the validity of the assay’s cutoffs.
Reproducibility
The IMMULITE 2000 assay demonstrated a total CV
across three sites of less than 10% (Table 2).
Table 1 Cutoffs of the VIDAS and IMMULITE 2000 CMV
IgM assays
VIDAS IMMULITE 2000
Signal/Cutoff
Ratio
Interpretation Signal/Cutoff
Ratio
Interpretation
< 0.7 Negative < 0.90 Nonreactive
≥ 0.7 to < 0.90 Equivocal 0.9 to < 1.1 Indeterminate
≥ 0.90 Positive ≥ 1.1 Reactive
Table 2 Reproducibility determined over 5 days at three
sites using 120 replicates per pool
Sample Days
(n)
Mean
(signal/
cutoff)
Within-
Run
(%)
Between-
Run
(%)
Between-
Site
(%)
Total
(%)
Pool 1 5 0.63 4.3 2.4 7 8.6
Pool 2 5 1.06 5.4 5.2 0.3 7.5
Pool 3 5 2.09 5.4 5.6 2.9 8.3
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Among healthy subjects, the 95th percentile signal/cut-
off value of 0.66 was supportive of the assay’s negative
cutoff of 0.9 (Table 3).
Method comparison
The positive, negative, and overall agreement between
the IMMULITE 2000 assay and the VIDAS assay for the
method comparison study population (n = 718) was >
95% (Table 4).
Potentially cross-reactive samples
In patients with potentially cross-reacting samples (n =
136), the IMMULITE 2000 CMV IgM assay had one
reactive sample and two indeterminate samples; simi-
larly, the VIDAS CMV IgM assay had one positive sam-
ple and two equivocal samples. The samples that were
VIDAS CMV IgM positive and equivocal were ANA
positive. One IMMULITE CMV IgM reactive sample
was RF positive. Of the IMMULITE CMV IgM indeter-
minate samples, one was ANA positive and the other
was RF positive. The overall agreement between the two
assays was approximately 96% (Table 5).
Immunocompromised patients
Overall agreement between the IMMULITE 2000 assay
and the predicate assay was ~96%, for the immunosup-
pressed, ~97% for the HIV-positive, and ~92% for trans-
plant subjects (Tables 6, 7, and 8). In the
immunosuppressed populati o n ,t h eV I D A Sa s s a yh a d
o n ep o s i t i v ea n do n ee q u i v o c a lr e s u l ta n dt h e
IMMULITE assay had two indeterminate results. In the
HIV-positive subjects, the VIDAS assay had one positive
and one equivocal result and the IMMULITE assay had
one reactive result. Among transplant subjects, the
VIDAS assay had one equivocal result.
Pregnancy
Overall agreement between the IMMULITE 2000 assay
and the predicate assay was approximately 97% (Table
9). The VIDAS assay had two reactive and two equivocal
results and the IMMULITE assay had three reactive and
three indeterminate results.
Discussion
CMV IgM can be detectable during new infection, reac-
tivated infection, or infected individuals who have been
recently re-exposed [4,6]. CMV IgM can aid in the diag-
nosis of primary infection, and it should be used in con-
junction with other clinical information.
The IMMULITE 2000 CMV IgM assay demonstrated
good reproducibility around the assay cutoffs with maxi-
mum total CV of 8.6% providing precise results. The
95
th percentile value of 0.66 in apparently healthy sub-
jects was far below the negative cutoff value of 0.90 sup-
porting this cutoff level. The IMMULITE CMV IgM
assay demonstrated comparable performance with the
VIDAS CMV IgM assay with an overall agreement in
the method comparison study population (n = 718) of
95%. Among the various subpopulations studied, the
overall agreement ranged from 91.7% to 96.7%.
Among patients with cross-reacting conditions, inter-
pretation of CMV IgM results may be challenging
because of the potential for false-positive results. In this
study of the 136 samples from patients with potentially
cross-reacting conditions, the reactive/positive and
Table 3 The mean, median, and 95th percentile values in
apparently healthy subjects by gender
Gender n 95th Percentile Mean (95% CI) Median (95% CI)
Female 62 0.77 0.27 (0.21 to 0.33) 0.19 (0.15 to 0.30)
Male 74 0.66 0.22 (0.17 to 0.26) 0.16 (0.13 to 0.18)
Total 136 0.66 0.24 (0.21 to 0.27) 0.17 (0.14 to 0.19)
Table 4 Overall method comparison results for the
IMMULITE 2000 and VIDAS CMV IgM assays
VIDAS
IMMULITE 2000 Positive Equivocal Negative Total
Reactive 98 (13.6%) 7 (1.0%) 9 (1.3%) 114 (15.9%)
Indeterminate 1 (0.1%) 2 (0.3%) 7 (1.0%) 10 (1.4%)
Nonreactive 3 (0.4%) 9 (1.3%) 582 (81.1%) 594 (82.7%)
Total 102 (14.2%) 18 (2.5%) 598 (83.3%) 718 (100%)
Agreement IMMULITE / VIDAS 95% CI
Positive 98/102 (96.1%) 90.3 to 98.9
Negative 582/598 (97.3%) 95.7 to 98.5
Overall 682/718 (95.0%) 93.1 to 96.5
Table 5 IMMULITE 2000 and VIDAS assays results and
agreement from patients with potentially cross-reactive
samples
Agreement IMMULITE / VIDAS 95% CI
Positive 0/1 (0%) 0 to 97.5
Negative 131/133 (98%) 94.7 to 99.8
Overall 133/136 (96%) 91.6 to 98.8
Table 6 IMMULITE 2000 and VIDAS CMV assay results
and agreement for samples from immunocompromised
subjects
Agreement IMMULITE / VIDAS 95% CI
Positive 0/1 (0.0%) 0 to 97.5
Negative 87/89 (97.8%) 92.1 to 99.7
Overall 87/91 (95.6%) 89.1 to 98.8
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were either ANA or RF positive (IMMULITE 2000
CMV IgM assay 3 results and VIDAS CMV IgM 3
results).
CMV infection can be serious and even fatal in preg-
nancy and in the immunocompromised [3-9]. Diagnosis
of active CMV infection can be accomplished through
detection of CMV DNA in body fluids; this approach
plays an important role in the immunocompromised
[8,9], and infants at risk for congenital disease [4]. This
study demonstrated a 92% to 96% agreement between
the IMMULITE 2000 and VIDAS CMV IgM assays
among immunocompromised patients. Among immuno-
compromised (transplant, HIV-infected or immunosup-
pressed) individuals CMV IgM and/or IgG antibodies
may be difficult to detect because of low titers, thus a
negative serology result should not be used in isolation
to rule-out infection [8].
CMV IgG seroprevalence, indicative of past infection,
among women of childbearing age ranges from 50% to
> 80% [4]. While seroconversion using only IgG antibo-
dies can be used to help determine when primary infec-
tion occurred, this is typically done retrospectively,
whereas, CMV IgM testing may aid in the diagnosis of
primary infection concurrently.
Diagnosis of primary CMV infection in pregnancy is
vital for establishing fetal infection risk because fetal
infection risk and serious sequelae are higher for pri-
mary infections [3,4]. Women who are seronegative for
CMV are at risk for contracting a primary infection dur-
ing pregnancy and have a much higher risk of transmit-
ting the virus to the fetus or neonate [3,4]. Furthermore,
transmission of the virus early in pregnancy is associated
with worse fetal outcomes [3]; thus CMV IgM testing
may facilitate earlier identification of high-risk pregnan-
cies and earlier fetal testing. The IMMULITE 2000
CMV IgM assay demonstrated excellent overall
agreement, 96.6%, with the VIDAS CMV IgM assay for
identification of primary infection in pregnant subjects.
Conclusions
The IMMULITE 2000 CMV IgM assay demonstrated
excellent reproducibility, minimal cross-reactivity, and
performance comparable to that of the VIDAS CMV
I g Ma s s a y .T h es a m p l ep o p u l a t i o ni n c l u d e dp r e g n a n t
women; immunosuppressed, transplant, and HIV-posi-
tive patients; and individuals with potentially cross-reac-
tive infections. The IMMULITE 2000 CMV IgM assay is
a tool that can aid clinicians in the diagnosis of CMV
infection. When it is combined with the IMMULITE
2000 CMV IgG assay and other IMMULITE 2000
ToRCH tests; it can help laboratories optimize consoli-
dation of their ToRCH testing.
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